MedTrace Logo

Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors

NCT03015324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-01-25

No results posted yet for this study

Summary

Hydroxychloroquine will be administered on an outpatient basis within 12 weeks after primary surgery followed by adjuvant chemotherapy /or radiation therapy (if needed). Hydroxychloroquine will be administered orally at a dose of 400 mg daily for 90 days. Subjects will receive HCQ every day.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine

Sponsors & Collaborators

  • Peng Wang, MD PhD

    lead OTHER

Principal Investigators

  • Peng Wang, MD, PhD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-08
Primary Completion
2020-02-03
Completion
2021-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015324 on ClinicalTrials.gov